Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals
Identifieur interne : 000586 ( Istex/Corpus ); précédent : 000585; suivant : 000587Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals
Auteurs : Nilesh P. Teli ; Michael P. TimkoSource :
- Plant Cell, Tissue and Organ Culture [ 0167-6857 ] ; 2004-11-01.
English descriptors
- KwdEn :
Abstract
Abstract: In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.
Url:
DOI: 10.1007/s11240-004-0653-0
Links to Exploration step
ISTEX:344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title><author><name sortKey="Teli, Nilesh P" sort="Teli, Nilesh P" uniqKey="Teli N" first="Nilesh P." last="Teli">Nilesh P. Teli</name><affiliation><mods:affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</mods:affiliation></affiliation></author><author><name sortKey="Timko, Michael P" sort="Timko, Michael P" uniqKey="Timko M" first="Michael P." last="Timko">Michael P. Timko</name><affiliation><mods:affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1007/s11240-004-0653-0</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000586</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000586</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title><author><name sortKey="Teli, Nilesh P" sort="Teli, Nilesh P" uniqKey="Teli N" first="Nilesh P." last="Teli">Nilesh P. Teli</name><affiliation><mods:affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</mods:affiliation></affiliation></author><author><name sortKey="Timko, Michael P" sort="Timko, Michael P" uniqKey="Timko M" first="Michael P." last="Timko">Michael P. Timko</name><affiliation><mods:affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Plant Cell, Tissue and Organ Culture</title><title level="j" type="sub">An International Journal on Biotechnology of Higher Plants</title><title level="j" type="abbrev">Plant Cell, Tissue and Organ Culture</title><idno type="ISSN">0167-6857</idno><idno type="eISSN">1573-5044</idno><imprint><publisher>Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><date type="published" when="2004-11-01">2004-11-01</date><biblScope unit="volume">79</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="125">125</biblScope><biblScope unit="page" to="145">145</biblScope></imprint><idno type="ISSN">0167-6857</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0167-6857</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>edible vaccines</term><term>molecular farming</term><term>plantibodies</term><term>secondary metabolites</term><term>therapeutic proteins</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Nilesh P. Teli</name><affiliations><json:string>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</json:string></affiliations></json:item><json:item><name>Michael P. Timko</name><affiliations><json:string>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>edible vaccines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>molecular farming</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>plantibodies</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>secondary metabolites</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>therapeutic proteins</value></json:item></subject><articleId><json:string>DO00000653</json:string><json:string>Art2</json:string></articleId><arkIstex>ark:/67375/VQC-WDZZ3DX9-1</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.</abstract><qualityIndicators><refBibsNative>false</refBibsNative><abstractWordCount>182</abstractWordCount><abstractCharCount>1266</abstractCharCount><keywordCount>5</keywordCount><score>9.184</score><pdfWordCount>12510</pdfWordCount><pdfCharCount>81587</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>21</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize></qualityIndicators><title>Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title><genre><json:string>research-article</json:string></genre><host><title>Plant Cell, Tissue and Organ Culture</title><language><json:string>unknown</json:string></language><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><issn><json:string>0167-6857</json:string></issn><eissn><json:string>1573-5044</json:string></eissn><journalId><json:string>11240</json:string></journalId><volume>79</volume><issue>2</issue><pages><first>125</first><last>145</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Plant Sciences</value></json:item><json:item><value>Plant Physiology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-WDZZ3DX9-1</json:string></ark><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1007/s11240-004-0653-0</json:string></doi><id>344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><availability><licence><p>Kluwer Academic Publishers, 2004</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2004</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title><author xml:id="author-0000"><persName><forename type="first">Nilesh</forename><surname>Teli</surname></persName><affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Michael</forename><surname>Timko</surname></persName><affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</affiliation></author><idno type="istex">344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9</idno><idno type="ark">ark:/67375/VQC-WDZZ3DX9-1</idno><idno type="DOI">10.1007/s11240-004-0653-0</idno><idno type="article-id">DO00000653</idno><idno type="article-id">Art2</idno></analytic><monogr><title level="j">Plant Cell, Tissue and Organ Culture</title><title level="j" type="sub">An International Journal on Biotechnology of Higher Plants</title><title level="j" type="abbrev">Plant Cell, Tissue and Organ Culture</title><idno type="pISSN">0167-6857</idno><idno type="eISSN">1573-5044</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">15</idno><idno type="volume-issue-count">3</idno><imprint><publisher>Kluwer Academic Publishers</publisher><pubPlace>Dordrecht</pubPlace><date type="published" when="2004-11-01"></date><biblScope unit="volume">79</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="125">125</biblScope><biblScope unit="page" to="145">145</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><item><term>edible vaccines</term></item><item><term>molecular farming</term></item><item><term>plantibodies</term></item><item><term>secondary metabolites</term></item><item><term>therapeutic proteins</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Life Sciences</head><item><term>Plant Sciences</term></item><item><term>Plant Physiology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2004-11-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Kluwer Academic Publishers</PublisherName><PublisherLocation>Dordrecht</PublisherLocation></PublisherInfo><Journal><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>11240</JournalID><JournalPrintISSN>0167-6857</JournalPrintISSN><JournalElectronicISSN>1573-5044</JournalElectronicISSN><JournalTitle>Plant Cell, Tissue and Organ Culture</JournalTitle><JournalSubTitle>An International Journal on Biotechnology of Higher Plants</JournalSubTitle><JournalAbbreviatedTitle>Plant Cell, Tissue and Organ Culture</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Life Sciences</JournalSubject><JournalSubject Type="Secondary">Plant Sciences</JournalSubject><JournalSubject Type="Secondary">Plant Physiology</JournalSubject></JournalSubjectGroup></JournalInfo><Volume><VolumeInfo VolumeType="Regular" TocLevels="0"><VolumeIDStart>79</VolumeIDStart><VolumeIDEnd>79</VolumeIDEnd><VolumeIssueCount>3</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular"><IssueInfo TocLevels="0"><IssueIDStart>2</IssueIDStart><IssueIDEnd>2</IssueIDEnd><IssueArticleCount>15</IssueArticleCount><IssueHistory><CoverDate><Year>2004</Year><Month>11</Month></CoverDate></IssueHistory><IssueCopyright><CopyrightHolderName>Kluwer Academic Publishers</CopyrightHolderName><CopyrightYear>2004</CopyrightYear></IssueCopyright></IssueInfo><Article ID="Art2"><ArticleInfo Language="En" ArticleType="OriginalPaper" NumberingStyle="Unnumbered" TocLevels="0" ContainsESM="No"><ArticleID>DO00000653</ArticleID><ArticleDOI>10.1007/s11240-004-0653-0</ArticleDOI><ArticleSequenceNumber>2</ArticleSequenceNumber><ArticleTitle Language="En">Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</ArticleTitle><ArticleFirstPage>125</ArticleFirstPage><ArticleLastPage>145</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2004</Year><Month>12</Month><Day>30</Day></RegistrationDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Kluwer Academic Publishers</CopyrightHolderName><CopyrightYear>2004</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants><ArticleContext><JournalID>11240</JournalID><VolumeIDStart>79</VolumeIDStart><VolumeIDEnd>79</VolumeIDEnd><IssueIDStart>2</IssueIDStart><IssueIDEnd>2</IssueIDEnd></ArticleContext></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Nilesh</GivenName><GivenName>P.</GivenName><FamilyName>Teli</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Michael</GivenName><GivenName>P.</GivenName><FamilyName>Timko</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Department of Biology</OrgDivision><OrgName>University of Virginia</OrgName><OrgAddress><Street>Gilmer Hall 044</Street><State>VA</State><Country>USA</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En"><Heading>Abstract</Heading><Para>In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.</Para></Abstract><KeywordGroup Language="En"><Keyword>edible vaccines</Keyword><Keyword>molecular farming</Keyword><Keyword>plantibodies</Keyword><Keyword>secondary metabolites</Keyword><Keyword>therapeutic proteins</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals</title></titleInfo><name type="personal"><namePart type="given">Nilesh</namePart><namePart type="given">P.</namePart><namePart type="family">Teli</namePart><affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael</namePart><namePart type="given">P.</namePart><namePart type="family">Timko</namePart><affiliation>Department of Biology, University of Virginia, Gilmer Hall 044, VA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Kluwer Academic Publishers</publisher><place><placeTerm type="text">Dordrecht</placeTerm></place><dateIssued encoding="w3cdtf">2004-11-01</dateIssued><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: In recent years there has been a dramatic increase in the application of plant biotechnology for the production of a variety of commercially valuable simple and complex biological molecules (biologics) for use in human and animal healthcare. Transgenic whole plants and plant cell culture systems have been developed that have the capacity to economically produce large-scale quantities of antibodies and antibody fragments, antigens and/or vaccine epitopes, metabolic enzymes, hormones, (neuro)peptides and a variety of biologically active complexes and secondary metabolites for direct use as therapeutic agents or diagnostic tools in the medical healthcare industry. As the products of genetically modified plants make their way from concept to commercialization the associated risks and acceptance by the public has been become a focal point. In this paper, we summarize the recent advances made in the use of transgenic plants and plant cell cultures as biological factories for the production of human therapeutics and biopharmaceuticals and discuss the long-term potential of `molecular farming' as a low-cost, efficient method for the production of biological materials with demonstrated utility to the pharmaceutical industry or medical community.</abstract><subject lang="en"><topic>edible vaccines</topic><topic>molecular farming</topic><topic>plantibodies</topic><topic>secondary metabolites</topic><topic>therapeutic proteins</topic></subject><relatedItem type="host"><titleInfo><title>Plant Cell, Tissue and Organ Culture</title><subTitle>An International Journal on Biotechnology of Higher Plants</subTitle></titleInfo><titleInfo type="abbreviated"><title>Plant Cell, Tissue and Organ Culture</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2004-11-01</dateIssued><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><subject><genre>Life Sciences</genre><topic>Plant Sciences</topic><topic>Plant Physiology</topic></subject><identifier type="ISSN">0167-6857</identifier><identifier type="eISSN">1573-5044</identifier><identifier type="JournalID">11240</identifier><identifier type="IssueArticleCount">15</identifier><identifier type="VolumeIssueCount">3</identifier><part><date>2004</date><detail type="volume"><number>79</number><caption>vol.</caption></detail><detail type="issue"><number>2</number><caption>no.</caption></detail><extent unit="pages"><start>125</start><end>145</end></extent></part><recordInfo><recordOrigin>Kluwer Academic Publishers, 2004</recordOrigin></recordInfo></relatedItem><identifier type="istex">344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9</identifier><identifier type="ark">ark:/67375/VQC-WDZZ3DX9-1</identifier><identifier type="DOI">10.1007/s11240-004-0653-0</identifier><identifier type="ArticleID">DO00000653</identifier><identifier type="ArticleID">Art2</identifier><accessCondition type="use and reproduction" contentType="copyright">Kluwer Academic Publishers, 2004</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Kluwer Academic Publishers, 2004</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-WDZZ3DX9-1/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000586 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000586 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:344BF381FCC6EBED62CE44FF2E24ADC83DD87BC9
|texte= Recent developments in the use of transgenic plants for the production of human therapeutics and biopharmaceuticals
}}
| This area was generated with Dilib version V0.6.33. |  |